HCW Biologics Inc. HCWB

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
21/100
Weak

Ranked against 712 peers in Biotechnology

About HCW Biologics Inc.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) … Full HCWB analysis →

Key strengths

  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.79), with robust interest coverage.
  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.81), suggesting sticky customer base.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 18.9th percentile with high volatility suggests weak pricing power or commoditized products.
  • ROIC Below WACC or Peers ROIC at 22.7th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
13
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where HCWB ranks in Biotechnology

HCW Biologics Inc. ranks #598 of 713 scored companies in Biotechnology by moat score — the top 84%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
594 Revelation Biosciences, Inc. REVBW 21/100 Weak
595 Synlogic, Inc. SYBX 21/100 Weak
596 Cognition Therapeutics, Inc. CGTX 21/100 Weak
597 Impact BioMedical, Inc. IBO 21/100 Weak
598 HCW Biologics Inc. HCWB 21/100 Weak
599 Mustang Bio, Inc. MBIO 21/100 Weak
600 Allarity Therapeutics, Inc. ALLR 21/100 Weak
601 Lyell Immunopharma, Inc. LYEL 21/100 Weak
602 Virpax Pharmaceuticals, Inc. VRPX 21/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How HCWB scores on the Corporate Default defenses

Pricing Power

Score 12 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 10 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 38 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 13 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 42 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 13 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding HCWB's moat

What is HCW Biologics Inc.'s moat score?

HCW Biologics Inc. (HCWB) scores 21 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #598 of 713 scored companies in Biotechnology, the top 84%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (42/100) and its weakest is Cost Advantage (10/100).

How does HCW Biologics Inc. compare with other Biotechnology companies?

HCW Biologics Inc. ranks #598 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Impact BioMedical, Inc. (IBO) at 21 just above it and Mustang Bio, Inc. (MBIO) at 21 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is HCW Biologics Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for HCW Biologics Inc.?

The Corporate Default template measures 6 defenses, and HCWB scores: Pricing Power (12), Cost Advantage (10), Customer Stickiness (38), Capital Efficiency (13), Resilience (42), Scale & Market Position (13). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000